Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Vrabec

Ophthalmology Rochester, MI Medical Doctor

NPI 1215985841 CMS profile 910116

1135 W University Dr Ste 155, Rochester, MI 48307

Open in the dashboard

General payments

$14,821

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Vrabec of Rochester, MI is reported in the CMS Open Payments database as having received $14,821 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $209 8
2024 General $2,798 16
2023 General $8,247 19
2022 General $3,292 35
2021 General $192 4
2020 General $40 1
2019 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Vrabec
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Joshua Vrabec were reported at $209. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Joshua Vrabec Ophthalmology median Middle half National median
2019 $43 $258 $104–$655 $163
2020 $40 $126 $45–$321 $114
2021 $192 $205 $76–$534 $132
2022 $3,292 $266 $100–$678 $149
2023 $8,247 $308 $117–$745 $160
2024 $2,798 $340 $127–$846 $164
2025 $209 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Carl Zeiss Meditec, Inc. $8,250 5 payments
  2. Carl Zeiss Meditec USA, Inc. $5,359 39 payments
  3. Alcon Vision LLC $702 22 payments
  4. Johnson & Johnson Surgical Vision, Inc. $140 6 payments
  5. RxSight Inc $124 5 payments
  6. Lensar, Inc. $115 1 payment
  7. Rayner Intraocular Lenses Limited $37 2 payments
  8. Glaukos Corporation $28 1 payment
  9. Bausch & Lomb Americas Inc. $22 1 payment
  10. Allergan Inc. $19 1 payment
  11. Other $25 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,425 5 payments
  2. Food and Beverage $3,681 74 payments
  3. Travel and Lodging $2,578 4 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,100 1 payment
  5. Gift $36 1 payment
Products named General payments · program years 2019–2025
  1. IOLMaster 700 $8,721 9 payments
  2. VisuMax $6,457 19 payments
  3. ARTEVO 800 $4,636 8 payments
  4. VERACITY SURGICAL $3,858 7 payments
  5. Humphrey HFA $3,575 2 payments
  6. FORUM $3,300 1 payment
  7. FORUM Glaucoma Workplace $3,300 1 payment
  8. CIRRUS HD-OCT Optical Tomography $3,025 3 payments
  9. QUATERA 700 $2,623 6 payments
  10. CIRRUS HD-OCT Optical Tomographer $2,163 3 payments
  11. Other $9,932 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

490

Median for Ophthalmology: 891

Drug cost

$25,582

Median for Ophthalmology: $68,233

Branded share of claims

18.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Multidose Cyclosporine Brand 13 $8,387
Lumigan Bimatoprost Brand 14 $7,741
Latanoprost Generic 246 $3,944
Prednisolone Acetate Generic 110 $3,693
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 42 $1,059
Timolol Maleate Generic 29 $372
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 22 $258
Brimonidine Tartrate Generic 14 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$183,306

Medicare's payments for the services billed

Medicare patients

421

Average age 75

Services billed

1,648

255 women, 166 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 43%
Ischemic heart disease 30%
Diabetes 28%
Chronic kidney disease 17%
Osteoporosis 17%
Depression 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record